BD Stent Clinical Studies & Publications

Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study.

Repici A, Vleggaar FP, Hassan C, van Boeckel PG, Romeo F, Pagano N, Malesci A, Siersema PD
Gastrointest Endosc. 2010 Nov;72(5):927-34
…21 patients were enrolled in the study … the biodegradable stent showed a favourable risk / benefit ratio, achieving complete relief of dysphagia in nearly 50% of RBES patients without the occurrence of major complications. The use of this stent may be a valuable alternative to repeat endoscopic dilation…

The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease

Griffiths EA, Gregory CJ, Pursnani KG, Ward JB, Stockwell RC
Surg Endosc. 2012 Aug;26(8):2367-75
…25 attempts at placing SX-ELLA biodegradable oesophageal stents were made … BD SX-ELLA oesophageal stents work well for the duration of their life span and result in significant improvements in dysphagia scores…

Endoscopic treatment of benign anastomotic esophagogastric strictures with a biodegradable stent

van Hooft JE, van Berge Henegouwen MI, Rauws EA, Bergman JJ, Busch OR, Fockens P
Gastrointest Endosc. 2011 May;73(5):1043-7.
…Conventional techniques are typically executed on an interval basis requiring multiple endoscopic procedures, the biodegradable stent causes a gradual dilation during several weeks … SX-ELLA biodegradable esophageal stent in patients with dysphagia caused by benign anastomotic esophageal strictures has promise in regard to efficacy and safety…

Study of the hydrolytic degradation of polydioxanone PPDX

The role of biodegradable stents in the management of benign and malignant oesophageal strictures: A cohort study
Stephen McCain a,*, Scott McCain a, Barry Quinn b, Ronan Gray a,c,
Joan Morton b, Paul Rice b
BD stenting has an excellent safety profile, with no major complications and no stent related mortality. It would appear to offer patients with benign disease greater than 50% possibility of long-term symptom resolution. For those who require re-intervention, the duration of absence of symptoms and re-intervention time is significantly longer than would be expected with either dilatation or SEMS or SEPS.